Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097877
Status:
COMPLETED
Last Update Posted:
2017-01-11
First Post:
2004-11-30
Brief Title:
Comparison of Biphasic Insulin Aspart 7030 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 7030 Versus Insulin Glargine in Combination With Metformin in Subjects With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in the United States of America USA The purpose of this study is to test whether Biphasic Insulin Aspart 7030 twice a day with Metformin improves glycemic control vs once daily Insulin Glargine with Metformin in subjects with Type 2 Diabetes who are inadequately controlled on basal insulin plus oral anti-diabetic therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None